Republication de : The impact of middle meatal steroid-eluting implants on the postoperative outcomes of chronic rhinosinusitis: A systematic review and meta-analysis

Q4 Medicine
A.M. Zamaili , Y.C. Kueh , S. Mohamad , B. Abdullah
{"title":"Republication de : The impact of middle meatal steroid-eluting implants on the postoperative outcomes of chronic rhinosinusitis: A systematic review and meta-analysis","authors":"A.M. Zamaili ,&nbsp;Y.C. Kueh ,&nbsp;S. Mohamad ,&nbsp;B. Abdullah","doi":"10.1016/j.aforl.2025.01.002","DOIUrl":null,"url":null,"abstract":"<div><div>Endoscopic sinus surgery (ESS) has become an established surgical option in refractory chronic rhinosinusitis (CRS). The goal of this review is to assess the impact of steroid-eluting middle meatal implants after ESS. Cochrane Central Register of Controlled Trials (CENTRAL), SCOPUS, PUBMED, and GOOGLE SCHOLAR were searched from inception to November 2022. All randomised controlled trials (RCTs) involving adult patients receiving ESS for CRS utilising a steroid-eluting middle meatal implants were eligible. The primary outcome was adhesion or synechiae. The secondary outcomes were mucosal inflammation, polyp reformation, the need for oral steroids and additional surgery, postoperative bleeding, sinus pain and discomfort, postoperative sinus-related infection, and change in intraocular pressure. Fourteen full articles were examined out of 496 potential abstracts. Seven RCTs satisfied the criteria. At 30<!--> <!-->days, steroid-eluting implants reduced adhesion (OR: 0.28, 95% CI: 0.14 to 0.56; <em>P</em> <!-->&lt;<!--> <!-->0.001), mucosal inflammation (MD: −13.09, 95% CI: −18.22 to −7.97; <em>P</em> <!-->&lt;<!--> <!-->0.001), polyp reformation (OR: 0.31; 95% CI: 0.22 to 0.44; <em>P</em> <!-->&lt;<!--> <!-->0.001), and requirement of additional oral steroid (OR: 0.44; 95% CI: 0.25 to 0.78; <em>P</em> <!-->=<!--> <!-->0.005) or surgery (OR: 0.25; 95% CI: 0.12 to 0.50; <em>P</em> <!-->&lt;<!--> <!-->0.001). While their use for adhesion (OR: 0.24; 95% CI: 0.11 to 0.54; <em>P</em> <!-->&lt;<!--> <!-->0.001) and polyp reformation (OR: 0.24; 95% CI: 0.12 to 0.51; <em>P</em> <!-->&lt;<!--> <!-->0.001) were favourable, there was no difference in mucosal inflammation (MD: −5.68, 95% CI: −12.39 to 1.03; <em>P</em> <!-->=<!--> <!-->0.100) or the need for surgery (OR: 0.96; 95% CI: 0.07 to 12.37; <em>P</em> <!-->=<!--> <!-->0.980) when evaluated after 30<!--> <!-->days. Overall, the findings suggest that steroid-eluting middle meatal implants improve ESS outcomes by lowering rates of adhesion formation, postoperative medical and surgical interventions, recurrent polyposis, and inflammation, while having no significant negative impact in the immediate postoperative period. More research is needed into the long-term impacts.</div></div>","PeriodicalId":38853,"journal":{"name":"Annales Francaises d''Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale","volume":"142 1","pages":"Pages 30-41"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales Francaises d''Oto-Rhino-Laryngologie et de Pathologie Cervico-Faciale","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879726125000026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Endoscopic sinus surgery (ESS) has become an established surgical option in refractory chronic rhinosinusitis (CRS). The goal of this review is to assess the impact of steroid-eluting middle meatal implants after ESS. Cochrane Central Register of Controlled Trials (CENTRAL), SCOPUS, PUBMED, and GOOGLE SCHOLAR were searched from inception to November 2022. All randomised controlled trials (RCTs) involving adult patients receiving ESS for CRS utilising a steroid-eluting middle meatal implants were eligible. The primary outcome was adhesion or synechiae. The secondary outcomes were mucosal inflammation, polyp reformation, the need for oral steroids and additional surgery, postoperative bleeding, sinus pain and discomfort, postoperative sinus-related infection, and change in intraocular pressure. Fourteen full articles were examined out of 496 potential abstracts. Seven RCTs satisfied the criteria. At 30 days, steroid-eluting implants reduced adhesion (OR: 0.28, 95% CI: 0.14 to 0.56; P < 0.001), mucosal inflammation (MD: −13.09, 95% CI: −18.22 to −7.97; P < 0.001), polyp reformation (OR: 0.31; 95% CI: 0.22 to 0.44; P < 0.001), and requirement of additional oral steroid (OR: 0.44; 95% CI: 0.25 to 0.78; P = 0.005) or surgery (OR: 0.25; 95% CI: 0.12 to 0.50; P < 0.001). While their use for adhesion (OR: 0.24; 95% CI: 0.11 to 0.54; P < 0.001) and polyp reformation (OR: 0.24; 95% CI: 0.12 to 0.51; P < 0.001) were favourable, there was no difference in mucosal inflammation (MD: −5.68, 95% CI: −12.39 to 1.03; P = 0.100) or the need for surgery (OR: 0.96; 95% CI: 0.07 to 12.37; P = 0.980) when evaluated after 30 days. Overall, the findings suggest that steroid-eluting middle meatal implants improve ESS outcomes by lowering rates of adhesion formation, postoperative medical and surgical interventions, recurrent polyposis, and inflammation, while having no significant negative impact in the immediate postoperative period. More research is needed into the long-term impacts.
中期金属类固醇洗脱植入物对慢性鼻窦炎术后预后的影响:系统回顾和荟萃分析
内窥镜鼻窦手术(ESS)已成为难治性慢性鼻窦炎(CRS)的一种确定的手术选择。本综述的目的是评估甾体洗脱中间金属植入物在ESS后的影响。检索了Cochrane Central Register of Controlled Trials (Central)、SCOPUS、PUBMED和谷歌SCHOLAR,检索时间从创立到2022年11月。所有随机对照试验(rct)均纳入使用类固醇洗脱的中间金属植入物接受ESS治疗CRS的成年患者。主要结局是粘连或粘连。次要结果是粘膜炎症、息肉重建、口服类固醇和额外手术的需要、术后出血、鼻窦疼痛和不适、术后鼻窦相关感染和眼压变化。从496篇潜在摘要中选取了14篇全文。7项rct符合标准。在第30天,类固醇洗脱植入物减少粘连(OR: 0.28, 95% CI: 0.14至0.56;P & lt;0.001),粘膜炎症(MD:−13.09,95% CI:−18.22 ~−7.97;P & lt;0.001),息肉重组(OR: 0.31;95% CI: 0.22 ~ 0.44;P & lt;0.001),以及额外口服类固醇的需求(OR: 0.44;95% CI: 0.25 ~ 0.78;P = 0.005)或手术(or: 0.25;95% CI: 0.12 ~ 0.50;P & lt;0.001)。而它们的粘附作用(OR: 0.24;95% CI: 0.11 ~ 0.54;P & lt;0.001)和息肉重组(OR: 0.24;95% CI: 0.12 ~ 0.51;P & lt;0.001)是有利的,粘膜炎症无差异(MD: - 5.68, 95% CI: - 12.39至1.03;P = 0.100)或是否需要手术(or: 0.96;95% CI: 0.07 ~ 12.37;P = 0.980)。总的来说,研究结果表明,类固醇洗脱的中间金属植入物通过降低粘连形成率、术后药物和手术干预、复发性息肉病和炎症来改善ESS结果,同时在术后立即没有明显的负面影响。需要对其长期影响进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
93
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信